WB
H
Endogenous
52
Rabbit IgG
#P06576
506
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu523 of human ATP5B protein.
Background
ATP5B (ATP5F1B) is the catalytic β subunit of the F1 portion of the F1F0 ATP synthase, which is responsible for the majority of ATP synthesis in oxidative phosphorylation (1). ATP5B is present in the inner membrane of mitochondria in all types of cells, where it functions as an ATP provider and plays an important role in maintaining intracellular energy homeostasis. A high level of ATP5B is associated with cancer proliferation, metastasis, and drug resistance (2-4). An increased level of ATP5B plays an important protective role in decreasing renal fibrosis (5). Cell surface expression of ATP5B has been found in various cell types, including tumor, endothelial, and neuronal cells (6), where it is involved in multiple biological processes depending on the cell types. These include promoting viral entry (7), serving as a ligand for tumor-T cell recognition (8), generating extracellular ATP, contributing to intracellular PH homeostasis (9), and facilitating tumor metastasis (10). Inhibition of ATP5B has been proposed as a potential treatment for aggressive cancer (11,12).
- Neupane, P. et al. (2019) Biomol Concepts 10, 1-10.
- Xu, G. and Li, J.Y. (2016) J Neurooncol 126, 405-13.
- Gale, M. et al. (2020) Cancer Res 80, 524-535.
- Wang, X. et al. (2021) FASEB J 35, e20649.
- Guan, S.S. et al. (2015) Sci Rep 5, 14561.
- Chang, H.Y. et al. (2012) Cancer Res 72, 4696-706.
- Ueda, K. and Suwanmanee, Y. (2022) Int J Mol Sci 23, 9570. doi: 10.3390/ijms23179570.
- Scotet, E. et al. (2005) Immunity 22, 71-80.
- Xing, S.L. et al. (2011) Cell Biol Int 35, 81-6.
- Li, W. et al. (2017) Int J Oncol 50, 1312-1320.
- Speransky, S. et al. (2019) Breast Cancer Res Treat 176, 271-289.
- Fliedner, S.M. et al. (2015) Am J Cancer Res 5, 1558-70.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.